Icaritin Improves Antibody-Induced Thrombocytopenia in a Mouse Model by Regulating T-cell Polarization

Abstract

Previous studies have shown that icaritin (ICT) has significant protective effects on immune thrombocytopenia (ITP), and the present study aimed to discuss the mechanism of this protective effect from the aspect of regulating T-cell polarization by an antibody-induced ITP mice model. Mice were given rat anti-mouse CD41 antibody (MWReg30) by intraperitoneal injection for 7 d to produce ITP model. At the same time, ICT was administrated at 10 mg/kg/d orally for 9 d. Peripheral blood platelets were counted by hematology analyzer. Spleen index was also tested. Spleen T-helper cell (Th), cytotoxic T-cell (CTL), Th1, Th2, Th17, regulatory T-cell (Treg), and follicular helper T-cell (Tfh) were quantified by flow cytometry. Serum Th1/Th2/Th17 cytokines were tested by mouse Th1/Th2/Th17 cytometric bead array (CBA) kit and transforming growth factor beta (TGF-β) were analyzed by enzyme-linked immunosorbent assay (ELISA) kit. The results indicated that ICT (10 mg/kg) protected against MWReg30-induced ITP, as evidenced by increased blood platelets and decreased spleen index. In addition, the imbalance of Th/CTL in ITP mice spleen was regulated by ICT. Meanwhile, ICT inhibited Th1, Th17, and Tfh and improved Th2 and Treg in ITP mice spleen. Furthermore, the results of CBA and ELISA suggested that ICT decreased serum Th1- and Th17-related cytokines and increased Th2 cytokines, as well as promoted the release of TGF-β. These results demonstrated that the protective effect of ICT on ITP was mediated by regulating T-cell polarization.

Key words

Icaritin - immune thrombocytopenia - T-cell polarization - helper T-cell - cytotoxic T-cell

• References

• 1 Cines DB, Cuker A, Semple JW. Pathogenesis of immune thrombocytopenia. Presse Med 2014; 43: e49-e59
• 2 Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008; 99: 4-13
• 3 Hoffmeister KM. The role of lectins and glycans in platelet clearance. J Thromb Haemost 2011; 9: 35-43
• 4 Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson L, Wadenvik H. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9: 1123-1124
• 5 Li J, van der Wal DE, Zhu G, Xu M, Yougbare I, Ma L, Vadasz B, Carrim N, Grozovsky R, Ruan M, Zhu L, Zeng Q, Tao L, Zhai Z, Peng J, Hou M, Leytin V, Freedman J, Hoffmeister K, Ni H. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun 2015; 6: 7737
• 6 Semple JW, Milev Y, Cosgrave D, Mody M, Hornstein A, Blanchette V, Freedman J. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996; 87: 4245-4254
• 7 Hu Y, Ma D, Shan N, Zhu Y, Liu X, Zhang L, Yu S, Ji C, Hou M. Increased number of Tc17 and correlation with Th17 cells in patients with immune thrombocytopenia. PLoS One 2011; 6: e26522
• 8 Xie J, Cui D, Liu Y, Jin J, Tong H, Wang L, Ruan G, Lu Y, Yuan H. Changes in follicular helper T-cells in idiopathic thrombocytopenic purpura patients. Int J Biol Sci 2015; 11: 220-229
• 9 Sakakura M, Wada H, Tawara I, Nobori T, Sugiyama T, Sagawa N, Shiku H. Reduced CD4+CD25+ T-cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 2007; 120: 187-193
• 10 Lai X, Ye Y, Sun C, Huang X, Tang X, Zeng X, Yin P, Zeng Y. Icaritin exhibits anti-inflammatory effects in the mouse peritoneal macrophages and peritonitis model. Int Immunopharmacol 2013; 16: 41-49
• 11 Li X, Hu Y, He L, Wang S, Zhou H, Liu S. Icaritin inhibits T-cell activation and prolongs skin allograft survival in mice. Int Immunopharmacol 2012; 13: 1-7
• 12 Wang C, Li K, Li W, Guo Y, Sun Y, Zhao X, Yao J, Li G, Pu X. Effects of anhydroicaritin microemulsion formulation on the immunologic bocytopenic purpura mice. Chinese J New Drugs 2017; 26: 555-561
• 13 McKenzie CG, Guo L, Freedman J, Semple JW. Cellular immune dysfunction in immune thrombocytopenia (ITP). Br J Haematol 2013; 163: 10-23
• 14 Qiu J, Liu X, Li X, Zhang X, Han P, Zhou H, Shao L, Hou Y, Min Y, Kong Z, Wang Y, Wei Y, Liu X, Ni H, Peng J, Hou M. CD8+ T-cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia. Sci Rep 2016; 6: 27445
• 15 Li S, Wang L, Zhao C, Li L, Peng J, Hou M. CD8+T-cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura. Br J Haematol 2007; 139: 605-611
• 16 Zhang J, Ma D, Zhu X, Qu X, Ji C, Hou M. Elevated profile of Th17, Th1 and Tc1 cells inpatients with immune thrombocytopenicpurpura. Haematologica 2009; 94: 1326-1329
• 17 Audia S, Samson M, Mahevas M, Ferrand C, Trad M, Ciudad M, Gautheron A, Seaphanh F, Leguy V, Berthier S, Salles B, Martin L, Lorcerie B, Ortega-Deballon P, Facy O, Caillot D, Soudry-Faure A, Michel M, Godeau B, Larmonier N, Saas P, Janikashvili N, Bonnotte B. Preferential splenic CD8 (+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. Blood 2013; 122: 2477-2486
• 18 Panitsas FP, Theodoropoulou M, Kouraklis A, Karakantza M, Theodorou GL, Zoumbos NC, Maniatis A, Mouzaki A. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 2004; 103: 2645-2647
• 19 Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K. The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases. Arch Immunol Ther Exp 2015; 63: 435-449
• 20 Rocha AM, Souza C, Rocha GA, de Melo FF, Clementino NC, Marino MC, Bozzi A, Silva ML, Martins Filho OA, Queiroz DM. The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia. Haematologica 2011; 96: 1560-1564
• 21 Wei Y, Hou M. T-cells in the pathogenesis of immune thrombocytopenia. Semin Hematol 2016; 53: S13-S15
• 22 Audia S, Rossato M, Santegoets K, Spijkers S, Wichers C, Bekker C, Bloem A, Boon L, Flinsenberg T, Compeer E, van den Broek T, Facy O, Ortega-Deballon P, Berthier S, Leguy-Seguin V, Martin L, Ciudad M, Samson M, Trad M, Lorcerie B, Janikashvili N, Saas P, Bonnotte B, Radstake TR. Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia. Blood 2014; 124: 2858-2866
• 23 Sanchez-Fueyo A, Sandner S, Habicht A, Mariat C, Kenny J, Zheng X, Strom T, Turka L, Sayegh M. Specificity of CD4+CD25+ regulatory T-cell function in alloimmunity. J Immunol 2006; 176: 329-334
• 24 Huber S, Schramm C, Lehr HA, Schmitt S, Becker C, Protschka M, Galle PR, Neurath MF, Blessing M. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T-cells. J Immunol 2004; 173: 6526-6531
• 25 Bao W, Bussel JB, Heck S, He W, Karpoff M, Boulad N, Yazdanbakhsh K. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 2010; 116: 4639-4645
• 26 Guo L, Kapur R, Aslam R, Speck ER, Zufferey A, Zhao Y, Kim M, Lazarus AH, Ni H, Semple JW. CD20+ B cell depletion therapy suppresses murine CD8+ T-cell-mediated immune thrombocytopenia (ITP). Blood 2016; 127: 735-738
• 27 Peng J. B cells help CD8+ T-cell responses. Blood 2016; 127: 667-669
• 28 Crow AR, Song S, Semple JW, Freedman J, Lazarus A. IVI g inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of antiidiotype reactivity. Br J Haematol 2001; 115: 679-686